Advertisement

Anaemia, but not iron deficiency, is associated with clinical symptoms and quality of life in patients with severe heart failure and palliative home care: A substudy of the PREFER trial

Published:September 09, 2017DOI:https://doi.org/10.1016/j.ejim.2017.08.027

      Highlights

      • In patients with advanced heart failure and palliative home care 54% had anaemia.
      • In these patients 47% also hade iron deficiency (ID).
      • Anaemia was associated with symptoms, quality of life and health-related questions.
      • ID was not associated with symptoms, quality of life and health-related questions.

      Abstract

      Background

      To explore the relationships between anaemia or iron deficiency (ID) and symptoms, quality of life (QoL), morbidity, and mortality.

      Methods

      A post-hoc, non-prespecified, explorative substudy of the prospective randomized PREFER trial. One centre study of outpatients with severe HF and palliative need managed with advanced home care. Associations between anaemia, ID, and the Edmonton Symptom Assessment Scale (ESAS), Euro QoL (EQ-5D), Kansas City Cardiomyopathy Questions (KCCQ) were examined only at baseline but at 6 months for morbidity and mortality.

      Results

      Seventy-two patients (51 males, 21 females), aged 79.2 ± 9.1 years. Thirty-nine patients (54%) had anaemia and 34 had ID (47%). Anaemia was correlated to depression (r = 0.37; p = 0.001), anxiety (r = 0.25; p = 0.04), and reduced well-being (r = 0.26; p = 0.03) in the ESAS; mobility (r = 0.33; p = 0.005), pain/discomfort (r = 0.27; p = 0.02), and visual analogue scale of health state (r = −0.28; p = 0.02) in the EQ-5D; and physical limitation (r = −0.27; p = 0.02), symptom stability; (r = −0.43; p < 0.001); (r = −0.25; p = 0.033), social limitation;(r = −0.26; p = 0.03), overall summary score; (r = −0.24, p = 0.046) and clinical summary score; (r = −0.27; p = 0.02) in the KCCQ. ID did not correlate to any assessment item. Anaemia was univariably associated with any hospitalization (OR: 3.0; CI: 1.05–8.50, p = 0.04), but not to mortality. ID was not significantly associated with any hospitalization or mortality.

      Conclusion

      Anaemia, but not ID, was associated although weakly with symptoms and QoL in patients with advanced HF and palliative home care.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Internal Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Ponikowski P.
        • Voors A.A.
        • Anker S.D.
        • Bueno H.
        • Cleland J.G.
        • Coats A.J.
        • et al.
        ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the heart failure association (HFA) of the ESC.
        Eur J Heart Fail. 2016; 18 (2016): 891-975
        • Klip I.T.
        • Comin-Colet J.
        • Voors A.A.
        • Ponikowski P.
        • Enjuanes C.
        • Banasiak W.
        • et al.
        Iron deficiency in chronic heart failure: an international pooled analysis.
        Am Heart J. 2013; 165 ([e3]): 575-582
        • Camaschella C.
        Iron-deficiency anemia.
        N Engl J Med. 2015; 373: 485-486
        • Jankowska E.A.
        • Malyszko J.
        • Ardehali H.
        • Koc-Zorawska E.
        • Banasiak W.
        • von Haehling S.
        • et al.
        Iron status in patients with chronic heart failure.
        Eur Heart J. 2013; 34: 827-834
        • Ponikowski P.
        • van Veldhuisen D.J.
        • Comin-Colet J.
        • Ertl G.
        • Komajda M.
        • Mareev V.
        • et al.
        Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency dagger.
        Eur Heart J. 2015; 36: 657-668
        • Comin-Colet J.
        • Lainscak M.
        • Dickstein K.
        • Filippatos G.S.
        • Johnson P.
        • Luscher T.F.
        • et al.
        The effect of intravenous ferric carboxymaltose on health-related quality of life in patients with chronic heart failure and iron deficiency: a subanalysis of the FAIR-HF study.
        Eur Heart J. 2013; 34: 30-38
        • Gutzwiller F.S.
        • Pfeil A.M.
        • Comin-Colet J.
        • Ponikowski P.
        • Filippatos G.
        • Mori C.
        • et al.
        Determinants of quality of life of patients with heart failure and iron deficiency treated with ferric carboxymaltose: FAIR-HF sub-analysis.
        Int J Cardiol. 2013; 168: 3878-3883
        • Jankowska E.A.
        • Rozentryt P.
        • Witkowska A.
        • Nowak J.
        • Hartmann O.
        • Ponikowska B.
        • et al.
        Iron deficiency predicts impaired exercise capacity in patients with systolic chronic heart failure.
        J Card Fail. 2011; 17: 899-906
        • Okonko D.O.
        • Mandal A.K.
        • Missouris C.G.
        • Poole-Wilson P.A.
        Disordered iron homeostasis in chronic heart failure: prevalence, predictors, and relation to anemia, exercise capacity, and survival.
        J Am Coll Cardiol. 2011; 58: 1241-1251
        • Brannstrom M.
        • Boman K.
        Effects of person-centred and integrated chronic heart failure and palliative home care. PREFER: a randomized controlled study.
        Eur J Heart Fail. 2014; 16: 1142-1151
        • Brannstrom M.
        • Boman K.A.
        New model for integrated heart failure and palliative advanced homecare—rationale and design of a prospective randomized study.
        European Journal of Cardiovascular Nursing: Journal of the Working Group on Cardiovascular Nursing of the European Society of Cardiology. 2013; 12: 269-275
        • Jonsson A.
        • Edner M.
        • Alehagen U.
        • Dahlstrom U.
        Heart failure registry: a valuable tool for improving the management of patients with heart failure.
        Eur J Heart Fail. 2010; 12: 25-31
        • Chang V.T.
        • Hwang S.S.
        • Feuerman M.
        Validation of the Edmonton symptom assessment scale.
        Cancer. 2000; 88: 2164-2171
        • EuroQol G.
        EuroQol—a new facility for the measurement of health-related quality of life.
        Health Policy. 1990; 16: 199-208
        • Ellis J.J.
        • Eagle K.A.
        • Kline-Rogers E.M.
        • Erickson S.R.
        Validation of the EQ-5D in patients with a history of acute coronary syndrome.
        Curr Med Res Opin. 2005; 21: 1209-1216
        • Patel H.
        • Ekman I.
        • Spertus J.A.
        • Wasserman S.M.
        • Persson L.O.
        Psychometric properties of a Swedish version of the Kansas City cardiomyopathy questionnaire in a chronic heart failure population.
        European Journal of Cardiovascular Nursing: Journal of the Working Group on Cardiovascular Nursing of the European Society of Cardiology. 2008; 7: 214-221
        • Walmsley T.A.
        • George P.M.
        • Fowler R.T.
        Colorimetric measurement of iron in plasma samples anticoagulated with EDTA.
        J Clin Pathol. 1992; 45: 151-154
        • Goodnough L.T.
        • Nemeth E.
        • Ganz T.
        Detection, evaluation, and management of iron-restricted erythropoiesis.
        Blood. 2010; 116: 4754-4761
        • Cooper T.J.
        • Anker S.D.
        • Comin-Colet J.
        • Filippatos G.
        • Lainscak M.
        • Luscher T.F.
        • et al.
        Relation of longitudinal changes in quality of life assessments to changes in functional capacity in patients with heart failure with and without anemia.
        Am J Cardiol. 2016; 117: 1482-1487
        • Fitzsimons S.
        • Doughty R.N.
        Iron deficiency in patients with heart failure.
        European Heart Journal Cardiovascular Pharmacotherapy. 2015; 1: 58-64
        • Jankowska E.A.
        • Rozentryt P.
        • Witkowska A.
        • Nowak J.
        • Hartmann O.
        • Ponikowska B.
        • et al.
        Iron deficiency: an ominous sign in patients with systolic chronic heart failure.
        Eur Heart J. 2010; 31: 1872-1880
        • Enjuanes C.
        • Klip I.T.
        • Bruguera J.
        • Cladellas M.
        • Ponikowski P.
        • Banasiak W.
        • et al.
        Iron deficiency and health-related quality of life in chronic heart failure: results from a multicenter European study.
        Int J Cardiol. 2014; 174: 268-275
        • Anker S.D.
        • Comin Colet J.
        • Filippatos G.
        • Willenheimer R.
        • Dickstein K.
        • Drexler H.
        • et al.
        Ferric carboxymaltose in patients with heart failure and iron deficiency.
        N Engl J Med. 2009; 361: 2436-2448
        • Goodnough L.T.
        Iron deficiency syndromes and iron-restricted erythropoiesis (CME).
        Transfusion. 2012; 52: 1584-1592
        • Pisaniello A.D.
        • Wong D.T.
        • Kajani I.
        • Robinson K.
        • Shakib S.
        Anaemia in chronic heart failure: more awareness is required.
        Intern Med J. 2013; 43: 999-1004